Optimalization of the response to influenza virus vaccination in breast cancer and colorectal cancer patients immunocompromised due to chemotherapy

Recruiting

• Conditions: bowel cancer; Breast cancer; Carcinoma of the breast; Colorectal cancer; 10047438; 10027655

• Registration Number: NL-OMON36140
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 190

Inclusion Criteria

1. Patients with breast cancer treated FEC- or TAC-containing triweekly chemotherapy at moment of vaccination.
2. Patients with colorectal cancer treated with Oxaliplatin-containing triweekly chemotherapy at moment of vaccination
3.Age >= 18 years
4. Signing informed consent

Exclusion Criteria

1. Fever at time of vaccination defined as a temperature of >= 38.5 °C.
2. Previous/known allergic reaction to any of the components of the vaccines given, for example hypersensitivity to egg protein
3. Thrombocytopenia (defined as < 50 * 109/L) at moment of vaccination

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Adequate rise in antibody titre</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Antibody titres against the influenza virus before and after vaccination.<br /><br>2. Ex vivo cellular immune response (cytokines, fine specificity) after<br /><br>vaccination</p><br>